126 related articles for article (PubMed ID: 35776191)
61. Recurrent Fusions Between YAP1 and KMT2A in Morphologically Distinct Neoplasms Within the Spectrum of Low-grade Fibromyxoid Sarcoma and Sclerosing Epithelioid Fibrosarcoma.
Puls F; Agaimy A; Flucke U; Mentzel T; Sumathi VP; Ploegmakers M; Stoehr R; Kindblom LG; Hansson M; Sydow S; Arbajian E; Mertens F
Am J Surg Pathol; 2020 May; 44(5):594-606. PubMed ID: 31913156
[TBL] [Abstract][Full Text] [Related]
62. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.
Reis H; Hager T; Wohlschlaeger J; Bauer S; Katenkamp K; Katenkamp D; Baba HA
Hum Pathol; 2013 Oct; 44(10):2266-74. PubMed ID: 23871289
[TBL] [Abstract][Full Text] [Related]
63. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma.
Palanisamy N; Ateeq B; Kalyana-Sundaram S; Pflueger D; Ramnarayanan K; Shankar S; Han B; Cao Q; Cao X; Suleman K; Kumar-Sinha C; Dhanasekaran SM; Chen YB; Esgueva R; Banerjee S; LaFargue CJ; Siddiqui J; Demichelis F; Moeller P; Bismar TA; Kuefer R; Fullen DR; Johnson TM; Greenson JK; Giordano TJ; Tan P; Tomlins SA; Varambally S; Rubin MA; Maher CA; Chinnaiyan AM
Nat Med; 2010 Jul; 16(7):793-8. PubMed ID: 20526349
[TBL] [Abstract][Full Text] [Related]
64. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25.
Ladanyi M; Lui MY; Antonescu CR; Krause-Boehm A; Meindl A; Argani P; Healey JH; Ueda T; Yoshikawa H; Meloni-Ehrig A; Sorensen PH; Mertens F; Mandahl N; van den Berghe H; Sciot R; Dal Cin P; Bridge J
Oncogene; 2001 Jan; 20(1):48-57. PubMed ID: 11244503
[TBL] [Abstract][Full Text] [Related]
65. High frequency of BRAF mutations in primary mucinous ovarian carcinoma of Taiwanese patients.
Chao WR; Lee YJ; Lee MY; Sheu GT; Han CP
Taiwan J Obstet Gynecol; 2021 Nov; 60(6):1072-1077. PubMed ID: 34794740
[TBL] [Abstract][Full Text] [Related]
66. RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma.
Smallridge RC; Chindris AM; Asmann YW; Casler JD; Serie DJ; Reddi HV; Cradic KW; Rivera M; Grebe SK; Necela BM; Eberhardt NL; Carr JM; McIver B; Copland JA; Thompson EA
J Clin Endocrinol Metab; 2014 Feb; 99(2):E338-47. PubMed ID: 24297791
[TBL] [Abstract][Full Text] [Related]
67. A Comparison of Morphologic and Molecular Features of BRAF, ALK, and NTRK1 Fusion Spitzoid Neoplasms.
Amin SM; Haugh AM; Lee CY; Zhang B; Bubley JA; Merkel EA; Verzì AE; Gerami P
Am J Surg Pathol; 2017 Apr; 41(4):491-498. PubMed ID: 27776007
[TBL] [Abstract][Full Text] [Related]
68. NCOA4-RET and TRIM27-RET Are Characteristic Gene Fusions in Salivary Intraductal Carcinoma, Including Invasive and Metastatic Tumors: Is "Intraductal" Correct?
Skálová A; Ptáková N; Santana T; Agaimy A; Ihrler S; Uro-Coste E; Thompson LDR; Bishop JA; Baněčkova M; Rupp NJ; Morbini P; de Sanctis S; Schiavo-Lena M; Vanecek T; Michal M; Leivo I
Am J Surg Pathol; 2019 Oct; 43(10):1303-1313. PubMed ID: 31162284
[TBL] [Abstract][Full Text] [Related]
69. A Molecular Study of Pediatric Spindle and Sclerosing Rhabdomyosarcoma: Identification of Novel and Recurrent VGLL2-related Fusions in Infantile Cases.
Alaggio R; Zhang L; Sung YS; Huang SC; Chen CL; Bisogno G; Zin A; Agaram NP; LaQuaglia MP; Wexler LH; Antonescu CR
Am J Surg Pathol; 2016 Feb; 40(2):224-35. PubMed ID: 26501226
[TBL] [Abstract][Full Text] [Related]
70. BRAFV600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration.
Flockhart RJ; Webster DE; Qu K; Mascarenhas N; Kovalski J; Kretz M; Khavari PA
Genome Res; 2012 Jun; 22(6):1006-14. PubMed ID: 22581800
[TBL] [Abstract][Full Text] [Related]
71. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway.
Pratilas CA; Taylor BS; Ye Q; Viale A; Sander C; Solit DB; Rosen N
Proc Natl Acad Sci U S A; 2009 Mar; 106(11):4519-24. PubMed ID: 19251651
[TBL] [Abstract][Full Text] [Related]
72. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation.
Heard JJ; Phung I; Potes MI; Tamanoi F
BMC Cancer; 2018 Jan; 18(1):69. PubMed ID: 29320991
[TBL] [Abstract][Full Text] [Related]
73. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
74. RREB1-MKL2 fusion in biphenotypic "oropharyngeal" sarcoma: New entity or part of the spectrum of biphenotypic sinonasal sarcomas?
Siegfried A; Romary C; Escudié F; Nicaise Y; Grand D; Rochaix P; Barres B; Vergez S; Chevreau C; Coindre JM; Uro-Coste E; Le Guellec S
Genes Chromosomes Cancer; 2018 Apr; 57(4):203-210. PubMed ID: 29266774
[TBL] [Abstract][Full Text] [Related]
75. Pleomorphic hyalinizing angiectatic tumor revisited: all tumors manifest typical morphologic features of myxoinflammatory fibroblastic sarcoma, further suggesting 2 morphologic variants of a single entity.
Michal M; Kazakov DV; Hadravský L; Agaimy A; Švajdler M; Kuroda N; Michal M
Ann Diagn Pathol; 2016 Feb; 20():40-3. PubMed ID: 26626209
[TBL] [Abstract][Full Text] [Related]
76. Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and/or mitogen-activated extracellular signal-regulated kinase inhibitors: A mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysis.
Dolladille C; Font J; Bejan-Angoulvant T; Zaman K; Sassier M; Ezine E; Stefan A; Plane AF; Legallois D; Milliez P; Parienti JJ; Alexandre J
Arch Cardiovasc Dis; 2020; 113(6-7):420-432. PubMed ID: 32418884
[TBL] [Abstract][Full Text] [Related]
77. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.
Boussemart L; Malka-Mahieu H; Girault I; Allard D; Hemmingsson O; Tomasic G; Thomas M; Basmadjian C; Ribeiro N; Thuaud F; Mateus C; Routier E; Kamsu-Kom N; Agoussi S; Eggermont AM; Désaubry L; Robert C; Vagner S
Nature; 2014 Sep; 513(7516):105-9. PubMed ID: 25079330
[TBL] [Abstract][Full Text] [Related]
78. BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series.
Butt SU; Mejias A; Morelli C; Torga G; Happe M; Patrikidou A; Arkenau HT
Cancer Chemother Pharmacol; 2021 Mar; 87(3):437-441. PubMed ID: 33537843
[TBL] [Abstract][Full Text] [Related]
79. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
80. Myxoinflammatory fibroblastic sarcoma showing t(2;6)(q31;p21.3) as a sole cytogenetic abnormality.
Ida CM; Rolig KA; Hulshizer RL; Van Dyke DL; Randolph JL; Jenkins RB; Nascimento AG; Oliveira AM
Cancer Genet Cytogenet; 2007 Sep; 177(2):139-42. PubMed ID: 17854670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
